Just before the holiday break, the FDA put an exclamation point on the number of new molecular entity (NMEs) approvals this year with two more medicines crossing the goal line. At the end of November, the count had ticked to 54 following the green light for Coral Gables, Fla.-based Catalyst Pharmaceuticals Inc.'s Firdapse (amifampridine phosphate), the first drug designated in the U.S. to treat adults with Lambert-Eaton myasthenic syndrome. Read More
It was a dramatic week on Wall Street spanning the Christmas holidays, with the Dow Jones Industrial Average plunging dramatically and then recovering to post a record climb of more than 1,000 points in one day. Not surprisingly, biopharma company equities were taken for a wild ride during the dramatic drop and subsequent recovery in the general markets. Read More
